In a randomized trial of semaglutide 2.4 mg vs placebo for 1 year, 529 participants with HFpEF with a BMI of 30 kg/m2, there was a very large reduction in symptoms, improvement in exercise function in the GLP-1 drug assigned group
Comparison with Other GLP-1 Receptor Agonists Comparison with Other GLP-1 Receptor Agonists When comparing Semaglutide with other GLP-1 receptor agonists (GLP-1 RAs), several factors come into play
Effects of Dietary Approach to Stop Hypertension diet on androgens, antioxidant status and body composition in overweight and obese women with polycystic ovary syndrome: a randomised controlled trial
80 So, while the results sound good, we have to view them as very low-quality evidence
Results showed that receiving methylcobalamin did not lead to any significant differences either in survival rates or ALS functional scores, when compared with placebo
Preventing missed doses The best missed dose is the one that never happens